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Background: Altered levels of specific matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases
(TIMPs) in the aqueous humour of primary open-angle glaucoma (POAG) eyes have been described. In this study,
levels of specific MMPs and TIMPs in the aqueous humour of primary angle-closure glaucoma (PACG) eyes were
measured and compared with those of POAG as well as non-glaucoma control eyes.
Methods: Aqueous humour from 16 PACG, 28 POAG and 27 control eyes were sampled during intraocular surgery.
Levels of total protein, MMP-2, MMP-3, TIMP-1 and TIMP-2 were quantified by protein assay and enzyme immunoassay.
Results: Total protein levels were significantly higher in PACG (0.426 ± 0.126 mg/ml, p = 0.043) and POAG (0.578 ±
0.360 mg/ml, p = 0.007) compared to controls (0.292 ± 0.192 mg/ml). The difference between PACG and POAG was not
significant (p = 0.158). MMP-2 was significantly higher in PACG (p = 0.032) and POAG (p < 0.001) compared to controls.
The difference between PACG and POAG was also not significant (p = 0.133). MMP-3 was significantly higher in POAG
compared to controls (p = 0.002) and PACG (p = 0.029). The difference between PACG and controls was not significant
(p = 0.962). TIMP-1 was significantly higher in PACG (p = 0.049) and POAG (p = 0.010) compared to controls. The
difference between PACG and POAG was also not significant (p = 0.961). TIMP-2 was significantly higher in POAG
(p = 0.004) compared to controls. The difference between PACG and either controls or POAG was not significant
(p > 0.05). Although not statistically significant (p > 0.05), the MMP-2/TIMP-2 ratio was highest in PACG (2.83 ± 7.40),
followed by POAG (1.38 ± 1.55) and controls (1.34 ± 3.05). Similarly, the MMP-2/TIMP-1 ratio was highest in PACG (1.50 ±
1.69), followed by POAG (1.40 ± 0.77) and controls (1.15 ± 0.92). The MMP-2 +MMP-3/TIMP-1 + TIMP-2 ratio was higher
in PACG (0.83 ± 0.80) and POAG (0.82 ± 0.53) compared to controls (0.70 ± 0.63). In both POAG and PACG, there were
no significant differences in the levels of total protein, MMP-2, MMP-3, TIMP-1 and TIMP-2 between patients on
prostaglandin analogues and those not.
Conclusion: We found altered levels of MMPs and TIMPs as well as imbalance of MMP:TIMP ratios in the aqueous
humour of PACG eyes that were different from POAG and non-glaucoma control eyes.
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The role of matrix metalloproteinases (MMPs) in de-
grading and remodelling extracellular matrix (ECM) is
well documented [1,2]. In the eye, abnormal expression
of MMPs has been implicated in corneal wound healing
[3], pterygia formation [4], proliferative diabetic retinop-
athy [5] and age-related macular degeneration [6]. In re-
lation to glaucoma, there is increasing awareness of their
implications in the pathogenesis of primary open angle
glaucoma (POAG) as well as uveitic and pseudoexfolia-
tive glaucoma [2,7-10], where enhanced presence and
activity of MMPs have been reported in the trabecular
meshwork, Schlemm’s canal and aqueous humour of
these diseased eyes.
MMPs are irreversibly inhibited in a 1:1 molar ratio by
their specific endogenous tissue inhibitors of metallopro-
teinases (TIMPs) and both are normally present in bal-
anced amounts [2,7-10]. The authors then suggest that
any imbalance between MMPs and TIMPs may result in
a change in ECM accumulation, which together with
impaired trabecular meshwork matrix turnover causes
increased aqueous humour outflow resistance and intra-
ocular pressure (IOP). This provides an explanation of
how altered levels of MMPs and TIMPs may upset the
regulation of aqueous humour outflow facility, which
may eventually lead to raised IOP and glaucoma.
Due to the high number of primary angle closure glau-
coma (PACG) cases in our population, and its nature of
being more visually destructive and difficult to manage
than POAG, we were determined to find out if MMPs
and TIMPs were present in balanced amounts in these
cases. We searched the literature and found scarce infor-
mation on eyes with PACG. In this study, we sought to
find out if there were any similarities or differences in
the levels of MMPs and TIMPs in PACG eyes, compared
to POAG and control eyes.
Prostaglandin analogues are used in the treatment of
glaucoma to reduce IOP. They increase MMP release by
the ciliary smooth muscle cells, which leads to an increase
in uveoscleral outflow [11,12]. We also looked into the ef-
fect of prostaglandin analogue use on the levels of total
proteins, MMP-2, −3, TIMP-1 and −2 in our separate
POAG and PACG groups.
Methods
Study design
This was a cross-sectional study involving patients
undergoing elective cataract or combination cataract
and trabeculectomy surgery at the University of Malaya
Medical Centre, Kuala Lumpur. Ethical approval was ob-
tained from the Medical Ethics Committee of the centre
prior to commencement of the study. All patients signed
a statement of informed consent in compliance with the
tenets of the Declaration of Helsinki for experimentsinvolving human tissue. POAG was diagnosed based on
the guidelines suggested by Foster et al. [13], specifically
when there was glaucomatous optic nerve head damage
(defined by the presence of neuroretinal rim loss of the
optic nerve head and vertical cup-disc ratio of 0.7 or
greater) with corresponding visual field loss. Eyes with
PACG had additional gonioscopic findings of angle clos-
ure (present when the trabecular meshwork was not
visualised in at least three quadrants on non-indentation
gonioscopy, with or without the presence of peripheral
anterior synechiae). Diagnoses were confirmed by two
fellowship-trained glaucoma specialists (AS and ZM).
The patients were on different numbers and combi-
nations of anti-glaucoma medications, including prosta-
glandin analogues, beta blockers, carbonic anhydrase
inhibitors and alpha-adrenergic agonists. Those who
had previous surgical procedures e.g. trabeculectomies
as well as those with uveitis, diabetes mellitus and
connective tissue disease were excluded. Additionally,
those who had peripheral iridotomies or acute angle
closure attacks in the preceding 1-year were also ex-
cluded. Patients with senile cataract with no evidence
of glaucoma served as the control group. All samples
were from different individuals.
Participants
A total of 33 (46.5%) male and 38 (53.5%) female pa-
tients participated in the study. Gender difference in
the whole group as well as in PACG, POAG and
control subgroups were not statistically significant
(p > 0.05) from Mann–Whitney tests. Approximately
80–100 μl of aqueous humour was aspirated using a
tuberculin syringe through an anterior chamber para-
centesis at the start of the surgical procedure. Care
was taken to avoid any contact with the inner struc-
tures of the eye and contamination with blood. The
samples were then transferred into micro-centrifuge
tubes, frozen in liquid nitrogen, stored at −80°C and
thawed just before analysis.
Estimation of protein, MMPs and TIMPs
Total aqueous humour protein levels were determined
by a commercially-available Pierce Bicinchoninic Acid
Protein Assay Kit (Thermo Scientific, IL, USA) with bo-
vine serum albumin as the standard. MMP-2, MMP-3,
TIMP-1 and TIMP-2 concentrations in the aqueous
humour were measured with commercially-available 96-
well enzyme immunoassay kits (Calbiochem, EMD Bio-
sciences, Inc., Germany). Assays were performed in
duplicate and a standard curve was plotted for each set.
The MMP-2 assay detected total MMP-1 (proMMP-2,
active MMP-2 and MMP-2:TIMP-2) complexes with a
sensitivity of 0.1 ng/ml while the MMP-3 assay detected
solely proMMP-3 with a sensitivity of 0.05 ng/ml. The
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0.0096 ng/ml and 3 ng/ml respectively.
Statistical analysis
Most of the data did not show normal distributions
when analysed using the One-Sample Kolmogorov-
Smirnov test. The non-parametric Kruskal-Wallis test
was thus used to compare the levels of total protein,
MMP-2, MMP-3, TIMP-1 and TIMP-2 between the
three groups. This was then followed by Dunn’s post-test
to determine the individual differences between the
groups. p < 0.05 was considered statistically significant.
Results
Table 1 presents the demography, pre-operative IOP
and number of medications of the control, PACG and
POAG subjects. The total protein content in the aque-
ous humour of control, PACG and POAG eyes were
0.292 ± 0.192 mg/ml, 0.426 ± 0.126 mg/ml and 0.578 ±
0.360 mg/ml respectively (mean ± SD, Figure 1). The
levels were significantly higher in the PACG and POAG
eyes compared to the control eyes (p = 0.043 and 0.007
respectively). Although the mean was lower in the PACG
eyes compared to the POAG eyes, the difference was not
significant (p = 0.158).
MMP-2 levels were significantly higher in the PACG
and POAG groups compared to the control group (p =
0.032 and <0.001 respectively, Figure 2). Although the
mean was higher in the POAG group compared to the
PACG group, the difference was not significant (p =
0.133). The level of MMP-3 was significantly higher in
the POAG group compared to control (p = 0.002) and
PACG (p = 0.029) groups (Figure 2). No significant dif-
ference was noted between the PACG and control
groups (p = 0.962).
TIMP-1 levels were significantly higher in PACG (p =
0.049) and POAG (p = 0.010) eyes compared to controls
(Figure 3). No significant difference was noted between
PACG and POAG eyes (p = 0.961). TIMP-2 levels were
significantly higher in POAG eyes compared to controls
(p = 0.004). There was no significant difference between
PACG and either control or POAG eyes (both p > 0.05).Table 1 Demography, preoperative IOP and medications
of subjects
Characteristics Control PACG POAG
n 27 (38.0%) 16 (22.5%) 28 (39.5%)
Gender (male/female) 13/14 5/11 15/13
Age (years) 66.8 ± 8.3 65.5 ± 9.4 68.4 ± 13.1
Preoperative IOP (mmHg) 14.3 ± 2.7 17.3 ± 6.0 18.4 ± 4.2
IOP medications (units) 0 2.00 ± 1.03 2.14 ± 1.04
Age and IOP data shown as mean ± standard deviation.When comparing various ratios of MMP to TIMP, the
results were all not statistically significant (p > 0.05).
However, the MMP-2/TIMP-2 ratio was highest in
PACG (2.83 ± 7.40), followed by POAG (1.38 ± 1.55) and
control eyes (1.34 ± 3.05) [Table 2]. A similar pattern
was seen in the ratio of MMP-2/TIMP-1, which was
highest in PACG (1.50 ± 1.69), followed by POAG
(1.40 ± 0.77) and control eyes (1.15 ± 0.92). When ratios of
the sum of MMPs-2 and −3/TIMPs-1 and −2 were calcu-
lated, the values were higher in the PACG (0.83 ± 0.80)
and POAG (0.82 ± 0.53) groups compared to controls
(0.70 ± 0.63).
Total protein, MMP-2, MMP-3, TIMP-1 and TIMP-2
levels were compared between patients on prostaglandin
analogues and those who were not, in both POAG and
PACG groups (Table 3). In the POAG patients, there
were no significant differences in the levels of total pro-
tein, MMP-2, MMP-3, TIMP-1 and TIMP −2 between
those who were on prostaglandin analogues and those
who were not. Similarly, in the PACG patients there
were no significant differences in the levels of total pro-
tein, MMP-2, MMP-3, TIMP-1 and TIMP-2 between pa-
tients who were on prostaglandin analogues and those
who were not.
Discussion
Differences in aqueous humour MMP and TIMP levels
between normal, PACG and POAG eyes were demon-
strated in this study. In POAG eyes, the higher levels of
both have been widely reported [2,7,9,10]. We found
that our PACG eyes also had higher levels of total pro-
tein, MMP-2 and TIMP-1 compared to normal eyes.
This implies a more active ECM degradation and re-
modelling process in the glaucomatous eyes. It is im-
portant to note that although the gelatinase MMP-2 is
not a collagenase, it does have collagen type I degrading
properties. Work investigating iris tissue composition in
PACG eyes has been reported. He et al. observed an in-
crease in mature collagen type I deposition in eyes that
have suffered acute symptomatic episodes of angle clos-
ure, along with their contralateral fellow eyes [14]. How-
ever, they found that the levels were lower in chronic
angle closure eyes. They went on to suggest that the de-
velopment of PACG could be due to a difference in the
ratio of collagen types I and III composition, which ul-
timately leads to a change in iris biomechanical proper-
ties and the development of PACG. The irides of PACG
eyes are also known to have higher levels of SPARC
(Secreted Protein, Acidic and Rich in Cysteine), which is
a matricellular protein that is secreted by fibroblasts,
endothelial cells and epithelial cells during an inflamma-
tory response to facilitate matrix remodelling and tissue
repair [15]. This protein is known to regulate the expres-
sion of several secreted ECM proteins and MMPs in
Figure 1 Boxplot showing mean and distribution of total protein in the aqueous humour of control, PACG and POAG eyes. The means
for the control, PACG and POAG groups were 0.292, 0.426 and 0.578 mg/ml respectively. The levels were significantly higher in the PACG and
POAG eyes compared to controls (p = 0.043 and 0.007 respectively).
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BM-40, SPARC binds to ECM proteins and cross-links
collagen fibrils, particularly that of type I, to increase
tensile strength and tissue rigidity. This change in iris ri-
gidity influences its biomechanics, which in turn plays
an important role in the development of angle closure
mechanisms.
Although not statistically significant, the levels of total
protein, MMP-2, TIMP-1 and TIMP-2 were lower in
PACG eyes when compared to POAG eyes. The level of
MMP-3 was significantly lower in PACG compared to in
POAG, and comparable to the non-glaucoma controls.
Seo et al. reported that PACG patients showed lowerFigure 2 Levels of MMPs in aqueous humour. MMP-2 levels were signif
group. The difference was not significant between the POAG and PACG gr
compared to the control and PACG groups. The difference was not significlevels of fibrosis and MMP expression in Tenon’s tissue
than POAG patients [17]. They suggested that the differ-
ence was due to involvement of distinctive pathological
mechanisms. In POAG, the location of aqueous humour
outflow obstruction is in the immediate vicinity of the
trabecular meshwork and Schlemm’s canal; on the
other hand, in PACG peripheral iris apposition blocks
aqueous humour access to the trabecular meshwork.
The authors remarked that these differences lead to the
differential expression of the MMPs and ECM between
the two conditions.
The evaluation of MMP/TIMP ratios was performed
to look at possible imbalances in ECM modulation. Dueicantly higher in the PACG and POAG groups compared to the control
oups. MMP-3 levels were significantly higher in the POAG group
ant between the PACG and control groups.
Figure 3 Levels of TIMPs in aqueous humour. TIMP-1 levels were significantly higher in PACG and POAG eyes compared to controls. No
significant difference was noted between PACG and POAG eyes. TIMP-2 levels were significantly higher in POAG eyes compared to controls. There
was no significant difference between PACG and either control or POAG eyes.
Table 3 Comparison between prostaglandin analogue use








Total protein (mg/ml) 0.67 ± 0.36 0.61 ± 0.49 0.404
MMP2 (ng/ml) 37.84 ± 23.53 32.08 ± 17.36 0.689
MMP3 (ng/ml) 14.88 ± 15.38 10.78 ± 16.21 0.063
TIMP1 (ng/ml) 32.18 ± 22.96 36.29 ± 41.44 0.742
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TIMP, the results were not statistically significant. How-
ever, the MMP-2/TIMP-2 ratio was highest in PACG
(2.83 ± 7.40), followed by POAG (1.38 ± 1.55) and con-
trols (1.34 ± 3.05). A similar pattern was seen in the ratio
of MMP-2/TIMP-1, which was highest in PACG (1.50 ±
1.69), followed by POAG (1.40 ± 0.77) and controls
(1.15 ± 0.92). When ratios of the sum of MMP-2 and
MMP-3 over the sum of TIMP-1 and TIMP-2 were cal-
culated, they were higher in PACG (0.83 ± 0.80) and
POAG (0.82 ± 0.53) compared to controls (0.70 ± 0.63).
Schlotzer-Schrehardt et al. reported MMP-2/TIMP-2 ra-
tios of 1.4 in POAG and 1.0 in control patients, and
MMP-2 +MMP-3 to TIMP-1 + TIMP-2 ratios of 0.15 in
POAG and 0.14 in control patients [7]. Fountoulakis
et al. reported MMP-2/TIMP-2 ratios of 4.04 in POAG
and 2.07 in control patients, and MMP-2/TIMP-1 ratios
of 0.81 in POAG and 0.46 in control patients [10]. The
exact measurements between studies vary perhaps due
to the large inter-individual variations or differences in
test kits but similar patterns can be seen. The ratios of
MMP-2/TIMP-2 and MMP-2/TIMP-1 were higher in
both POAG and PACG groups compared to controls,
and higher in PACG than in POAG. When MMP-2 +Table 2 Ratios of MMP to TIMP
Diagnosis MMP-2/TIMP-2 MMP-2/TIMP-1 MMP-2 + 3 to
TIMP-1 + 2
Control 1.34 ± 3.05 1.15 ± 0.92 0.70 ± 0.63
PACG 2.83 ± 7.40 1.50 ± 1.69 0.83 ± 0.80
POAG 1.38 ± 1.55 1.40 ± 0.77 0.82 ± 0.53
P-value 0.732 0.309 0.372
No significant differences between control/PACG/POAG groups for all
combinations on Kruskal-Wallis tests.MMP-3 and TIMP-1 + TIMP-2 were expressed as a ra-
tio, TIMPs appeared in excess of MMPs. The ratios were
also highest in the PACG group, followed by the POAG
and control groups. We thus observed a change in the
balance of MMPs and TIMPs in PACG and POAG eyes
when compared to controls. This supports the current
understanding that an imbalance between MMPs and
their inhibitors is a key factor in abnormal matrix accu-
mulation and causal involvement in the pathogenesis of
POAG. Additionally, we conclude that this process oc-
curs in PACG as well. From our findings and those by
He et al. and Chua et al. [14,16], we believe that PACG
eyes exhibit higher levels of MMPs and TIMPs due toTIMP2 (ng/ml) 61.56 ± 62.17 37.80 ± 29.16 0.375
PACG
n 9 7
Total protein (mg/ml) 0.47 ± 0.12 0.39 ± 0.13 0.899
MMP2 (ng/ml) 25.28 ± 12.73 29.07 ± 19.79 0.837
MMP3 (ng/ml) 20.02 ± 45.69 4.31 ± 2.48 0.692
TIMP1 (ng/ml) 43.81 ± 44.14 29.84 ± 14.77 0.681
TIMP2 (ng/ml) 47.52 ± 40.11 30.85 ± 22.33 0.408
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ther definitive studies which will shed more light into
the pathogenesis of this blinding disease.
There were no significant differences in total protein,
MMPs and TIMPs between our prostaglandin analogue
treated eyes and those without, in both POAG and
PACG groups. We are unclear about the cause of this
but it may not be a representative picture as most of
our glaucoma patients were on multiple anti-glaucoma
agents, which could be a confounding factor modifying
the levels of aqueous humour proteins, MMPs and
TIMPs. This situation could have been prevented by
analysing only those on monotherapy with prostaglan-
din analogues, but this was not performed as the num-
ber of patients was small (n = 2 in both POAG and
PACG groups).
We recognise several other limitations of our study.
We measured only MMP-2, MMP-3, TIMP-1 and
TIMP-2. In future, we recommend measuring the levels
of MMP1, MMP-8 and MMP-13 which are the specific
collagenases that degrade collagen type I in particular.
We also acknowledge the fact that previous acute angle
closure attacks or laser peripheral iridotomy in PACG
eyes could exert a local inflammatory effect and account
for the observed differences in MMPs and TIMPs be-
tween the PACG and normal eyes. We did however ex-
clude PACG cases with recent (within 1-year of aqueous
sampling) peripheral iridotomies or attacks of acute
angle closure for this study. Finally, we also included pa-
tients with systemic hypertension. This condition is as-
sociated with higher levels of circulating plasma MMP-2,
MMP-9 and TIMP-1, which may also have affected our
measurements [18].
Conclusion
Our studies showed altered levels of MMPs and TIMPs,
as well as unbalanced MMP:TIMP ratios in PACG eyes
that were slightly different from those of POAG. These
changes could be due to different expression of MMPs
and TIMPs, and subsequent differences in ECM remod-
elling in the two conditions.
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